Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4094252
Max Phase: Preclinical
Molecular Formula: C20H21N5O2
Molecular Weight: 363.42
Molecule Type: Small molecule
Associated Items:
ID: ALA4094252
Max Phase: Preclinical
Molecular Formula: C20H21N5O2
Molecular Weight: 363.42
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(NC1COC1)c1cc2c(N3CCCC3c3ccccn3)ccnc2[nH]1
Standard InChI: InChI=1S/C20H21N5O2/c26-20(23-13-11-27-12-13)16-10-14-17(6-8-22-19(14)24-16)25-9-3-5-18(25)15-4-1-2-7-21-15/h1-2,4,6-8,10,13,18H,3,5,9,11-12H2,(H,22,24)(H,23,26)
Standard InChI Key: JHSXSAMKAGPNIF-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 363.42 | Molecular Weight (Monoisotopic): 363.1695 | AlogP: 2.43 | #Rotatable Bonds: 4 |
Polar Surface Area: 83.14 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.90 | CX Basic pKa: 6.10 | CX LogP: 1.37 | CX LogD: 1.35 |
Aromatic Rings: 3 | Heavy Atoms: 27 | QED Weighted: 0.74 | Np Likeness Score: -0.87 |
1. Rahm F, Viklund J, Trésaugues L, Ellermann M, Giese A, Ericsson U, Forsblom R, Ginman T, Günther J, Hallberg K, Lindström J, Persson LB, Silvander C, Talagas A, Díaz-Sáez L, Fedorov O, Huber KVM, Panagakou I, Siejka P, Gorjánácz M, Bauser M, Andersson M.. (2018) Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug Design., 61 (6): [PMID:29485874] [10.1021/acs.jmedchem.7b01884] |
Source(1):